FSM Wealth Advisors LLC Invests $427,000 in Medtronic PLC $MDT

FSM Wealth Advisors LLC bought a new stake in shares of Medtronic PLC (NYSE:MDT) during the 2nd quarter, Holdings Channel.com reports. The firm bought 4,872 shares of the medical technology company’s stock, valued at approximately $427,000.

A number of other institutional investors and hedge funds have also recently bought and sold shares of the stock. 1248 Management LLC purchased a new stake in Medtronic during the 1st quarter worth $26,000. Columbia River Financial Group LLC acquired a new position in shares of Medtronic in the 1st quarter valued at approximately $28,000. Twin Tree Management LP purchased a new position in shares of Medtronic during the 1st quarter valued at approximately $29,000. Activest Wealth Management grew its position in shares of Medtronic by 3,577.8% during the first quarter. Activest Wealth Management now owns 331 shares of the medical technology company’s stock worth $30,000 after buying an additional 322 shares in the last quarter. Finally, Hughes Financial Services LLC bought a new stake in shares of Medtronic in the 1st quarter worth about $32,000. Hedge funds and other institutional investors own 82.06% of the company’s stock.

Medtronic Trading Down 1.7%

Shares of NYSE MDT opened at $94.25 on Friday. The company has a market cap of $120.89 billion, a price-to-earnings ratio of 25.96, a price-to-earnings-growth ratio of 2.53 and a beta of 0.78. Medtronic PLC has a 12-month low of $79.29 and a 12-month high of $99.37. The company has a current ratio of 2.01, a quick ratio of 1.50 and a debt-to-equity ratio of 0.54. The stock’s 50 day simple moving average is $94.31 and its 200 day simple moving average is $89.25.

Medtronic (NYSE:MDT) last issued its quarterly earnings data on Tuesday, August 19th. The medical technology company reported $1.26 EPS for the quarter, topping analysts’ consensus estimates of $1.23 by $0.03. Medtronic had a return on equity of 14.61% and a net margin of 13.63%.The firm had revenue of $8.58 billion during the quarter, compared to the consensus estimate of $8.37 billion. During the same period in the prior year, the business earned $1.23 EPS. The firm’s revenue was up 7.7% on a year-over-year basis. Medtronic has set its FY 2026 guidance at 5.600-5.660 EPS. Equities research analysts expect that Medtronic PLC will post 5.46 EPS for the current year.

Medtronic Announces Dividend

The company also recently disclosed a quarterly dividend, which was paid on Friday, October 17th. Investors of record on Friday, September 26th were issued a $0.71 dividend. This represents a $2.84 dividend on an annualized basis and a dividend yield of 3.0%. The ex-dividend date of this dividend was Friday, September 26th. Medtronic’s dividend payout ratio (DPR) is 78.24%.

Analysts Set New Price Targets

Several brokerages recently weighed in on MDT. Evercore ISI boosted their price objective on Medtronic from $103.00 to $106.00 and gave the company an “outperform” rating in a report on Tuesday, July 8th. Wells Fargo & Company boosted their price target on Medtronic from $98.00 to $100.00 and gave the company an “overweight” rating in a report on Wednesday, August 20th. William Blair raised Medtronic to a “hold” rating in a research report on Friday, July 11th. Robert W. Baird lifted their price objective on shares of Medtronic from $94.00 to $96.00 and gave the stock a “neutral” rating in a report on Wednesday, August 20th. Finally, Wall Street Zen lowered shares of Medtronic from a “buy” rating to a “hold” rating in a research note on Friday, October 3rd. One equities research analyst has rated the stock with a Strong Buy rating, twelve have assigned a Buy rating, nine have given a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat, the stock presently has an average rating of “Moderate Buy” and an average price target of $102.82.

Insider Activity

In related news, EVP Harry Skip Kiil sold 8,605 shares of Medtronic stock in a transaction dated Wednesday, September 3rd. The shares were sold at an average price of $91.58, for a total value of $788,045.90. Following the sale, the executive vice president directly owned 35,615 shares in the company, valued at $3,261,621.70. This trade represents a 19.46% decrease in their position. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. Also, Director William R. Jellison bought 2,500 shares of Medtronic stock in a transaction on Monday, August 25th. The shares were purchased at an average cost of $92.37 per share, with a total value of $230,925.00. Following the completion of the purchase, the director directly owned 5,000 shares in the company, valued at $461,850. This trade represents a 100.00% increase in their ownership of the stock. The disclosure for this purchase can be found here. Company insiders own 0.26% of the company’s stock.

Medtronic Profile

Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.